Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
TARA - Protara Therapeutics, Inc.
Market Cap 28.38M P/E - EPS this Y 14.30% Ern Qtrly Grth -
Income -40.69M Forward P/E -0.79 EPS next Y -4.60% 50D Avg Chg -7.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -18.00%
Dividend N/A Price/Book 0.30 EPS next 5Y - 52W High Chg -45.00%
Recommedations 1.40 Quick Ratio 15.86 Shares Outstanding 20.63M 52W Low Chg 14.00%
Insider Own 6.13% ROA -28.11% Shares Float 15.17M Beta 1.85
Inst Own 51.36% ROE -45.91% Shares Shorted/Prior 2.10M/1.88M Price 2.51
Gross Margin - Profit Margin - Avg. Volume 34,432 Target Price 26.40
Oper. Margin - Earnings Date Nov 1 Volume 42,949 Change -1.18%
Healthcare | Biotechnology | United States
About Protara Therapeutics, Inc.

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy that is in Phase II clinical trial for patients receiving parenteral nutrition. The company is headquartered in New York, New York.

Protara Therapeutics, Inc. News
12/11/24 Protara Announces Closing of $100 Million Public Offering
12/09/24 Protara Announces Pricing of $100 Million Public Offering
12/09/24 Protara Announces Proposed Public Offering
12/07/24 Institutions profited after Protara Therapeutics, Inc.'s (NASDAQ:TARA) market cap rose US$60m last week but individual investors profited the most
12/05/24 Protara Announces Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC
12/03/24 Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5, 2024
11/15/24 Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
11/12/24 Protara Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
11/06/24 Protara Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference
10/21/24 Protara Therapeutics Granted FDA Fast Track Designation for Intravenous Choline Chloride for Patients Receiving Parenteral Support
09/09/24 Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
09/09/24 Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support
09/03/24 Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/08/24 Will Protara Therapeutics (NASDAQ:TARA) Spend Its Cash Wisely?
08/06/24 Protara Therapeutics Announces Second Quarter 2024 Financial Results and Provides a Business Update
06/24/24 Protara Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05/21/24 Protara Therapeutics to Present at the TD Cowen 5th Annual Oncology Innovation Summit
05/02/24 Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
04/05/24 Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
04/05/24 Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Opaleye Management Inc. 10% Owner 10% Owner Dec 30 Sell 2.71 15,473 41,932 130,000 12/30/22
Opaleye Management Inc. 10% Owner 10% Owner Sep 14 Buy 3.89 23,900 92,971 132,300 09/15/22
Shefferman Jesse CEO and President CEO and President Aug 11 Buy 3.84 9,065 34,810 879,441 08/15/22
Opaleye Management Inc. 10% Owner 10% Owner Apr 07 Buy 4.77 10,136 48,349 127,500 04/15/22
BESHAR LUKE M Director Director Mar 14 Buy 4.25 10,000 42,500 188,000 03/16/22
BESHAR LUKE M Director Director Mar 10 Buy 4.4555 10,000 44,555 178,000 03/14/22
Opaleye Management Inc. 10% Owner 10% Owner Dec 28 Buy 6.57 11,591 76,153 120,000 12/29/21
Opaleye Management Inc. 10% Owner 10% Owner Dec 23 Buy 6.57 38,000 249,660 110,000 12/27/21
Marshall Randall - - Sep 15 Sell 19.63 2,554 50,135 585,600 09/15/20